Immunotherapy that blocks the interaction between programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has been very effective against different types of cancers such as melanoma, Hodgkin’s lymphoma, colorectal cancer and non-small-cell lung cancer16. Here, PDCD1 is linked to cancer.